Analysts Anticipate Affimed N.V. (AFMD) Will Announce Quarterly Sales of $1.42 Million

Equities analysts expect Affimed N.V. (NASDAQ:AFMD) to report $1.42 million in sales for the current quarter, according to Zacks. Three analysts have issued estimates for Affimed N.V.’s earnings. The lowest sales estimate is $440,000.00 and the highest is $2.16 million. Affimed N.V. reported sales of $2.34 million during the same quarter last year, which would suggest a negative year over year growth rate of 39.3%. The company is expected to report its next earnings report on Wednesday, August 9th.

According to Zacks, analysts expect that Affimed N.V. will report full-year sales of $1.42 million for the current year, with estimates ranging from $1.78 million to $15.00 million. For the next fiscal year, analysts forecast that the business will report sales of $12.31 million per share, with estimates ranging from $1.78 million to $30.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Affimed N.V..

Affimed N.V. (NASDAQ:AFMD) last issued its quarterly earnings results on Wednesday, May 17th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.03. The company had revenue of $1.94 million for the quarter, compared to analyst estimates of $1.73 million. Affimed N.V. had a negative return on equity of 68.94% and a negative net margin of 655.80%. The company’s quarterly revenue was up 385.0% compared to the same quarter last year. During the same period last year, the company earned ($0.25) earnings per share.

AFMD has been the topic of several research reports. Zacks Investment Research lowered Affimed N.V. from a “buy” rating to a “hold” rating in a research note on Wednesday, March 22nd. Oppenheimer Holdings, Inc. set a $10.00 price target on Affimed N.V. and gave the company a “buy” rating in a research note on Thursday, May 18th. Finally, Jefferies Group LLC upped their price target on Affimed N.V. to $2.50 and gave the company a “hold” rating in a research note on Wednesday, April 26th.

TRADEMARK VIOLATION NOTICE: “Analysts Anticipate Affimed N.V. (AFMD) Will Announce Quarterly Sales of $1.42 Million” was first published by Mideast Time and is owned by of Mideast Time. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.mideasttime.com/analysts-anticipate-affimed-n-v-afmd-will-announce-quarterly-sales-of-1-42-million/1808473.html.

A number of large investors have recently added to or reduced their stakes in the stock. Creative Planning increased its stake in Affimed N.V. by 30.0% in the first quarter. Creative Planning now owns 65,000 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 15,000 shares in the last quarter. Nationwide Fund Advisors increased its stake in Affimed N.V. by 9,542.0% in the first quarter. Nationwide Fund Advisors now owns 484,027 shares of the biopharmaceutical company’s stock worth $1,113,000 after buying an additional 479,007 shares in the last quarter. Perceptive Advisors LLC bought a new stake in Affimed N.V. during the fourth quarter worth approximately $1,322,000. Tekla Capital Management LLC increased its stake in Affimed N.V. by 377.7% in the first quarter. Tekla Capital Management LLC now owns 1,405,324 shares of the biopharmaceutical company’s stock worth $3,232,000 after buying an additional 1,111,111 shares in the last quarter. Finally, NEA Management Company LLC bought a new stake in Affimed N.V. during the first quarter worth approximately $8,944,000. Institutional investors and hedge funds own 42.43% of the company’s stock.

Shares of Affimed N.V. (NASDAQ:AFMD) traded down 1.20% on Wednesday, hitting $2.05. The stock had a trading volume of 264,013 shares. The firm has a 50 day moving average price of $2.21 and a 200-day moving average price of $2.18. Affimed N.V. has a 52 week low of $1.65 and a 52 week high of $3.32. The company’s market cap is $90.07 million.

Affimed N.V. Company Profile

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:AFMD”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Get a free copy of the Zacks research report on Affimed N.V. (AFMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Affimed N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed N.V. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.